LitAlert ~~ GeneLit.com

    • PDGFRß is an essential therapeutic target for BRCA1-deficient mammary tumors.
    • Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH.
    • Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x.
    • The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
    • Molnár S, Vida B, Beke L, Méhes G, Póka R.
    • Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
    • Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
    • Brown LC, Salgado R, Luen SJ, Savas P, Loi S.
    • Cancer J. 2021 Jan-Feb 01;27(1):25-31. doi: 10.1097/PPO.0000000000000501.
    • Review
    • PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
    • Layman RM, Arun B.
    • Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.
    • Review